Drugs / SHR7390
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03182673 | Jul 2017 → Jun 2019 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT02968485 | Nov 2016 → Apr 2019 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04676607 | Dec 2020 → Jun 2023 | prostate carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 2 | NCT04355858 | May 2020 → May 2023 | breast cancer, metastatic malignant neoplasm | Fudan University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR7390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02968485 ↗ |
| Action | Inhibit | “MEK inhibitor” NCT02968485 ↗ |
| Route | Oral | “Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.” NCT02968485 ↗ |